C

    Cytokinetics Inc (CYTK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $70.91
    -1.18 (-1.64%)

    Market Cap: $10.02B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(16/40)
    Avg Surprise
    +6.96%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.43
    Range$-1.65 - $-1.10
    16 analysts
    EPS Revisions
    3
    0
    7d
    5
    1
    30d
    EPS Estimate Drift
    90d ago$-1.59-11.1%
    60d ago$-1.59-11.1%
    30d ago$-1.55-8.1%
    7d ago$-1.44-0.9%
    Current$-1.43
    Revenue Consensus
    $40M
    Range$28M - $51M
    19 analysts
    Dec 31, 2026
    EPS Consensus$-1.28
    Range$-1.72 - $-0.08
    16 analysts
    Revenue Consensus
    $83M
    Range$44M - $156M
    20 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.28---
    Sep 26EST
    		-$-1.43---
    Jun 26
    		$-1.50$-1.63+7.98%Beat-33.9%
    Mar 26
    		$-1.67$-1.65-1.21%Miss-22.8%
    Dec 25
    		$-1.50$-1.56+3.85%Beat-19.0%
    Sep 25
    		$-1.54$-1.59+3.14%Beat-13.2%
    Jun 25
    		$-1.12$-1.34+16.42%Beat+14.5%
    Mar 25
    		$-1.36$-1.36+0.00%Beat-2.3%
    Dec 24
    		$-1.26$-1.17-7.33%Miss+8.7%
    Sep 24
    		$-1.36$-1.24-9.68%Miss-0.7%
    Jun 24
    		$-1.31$-0.91-43.96%Miss+2.2%
    Mar 24
    		$-1.33$-1.17-13.68%Miss+3.6%
    Dec 23
    		$-1.38$-0.97-42.27%Miss+4.8%
    Sep 23
    		$-1.35$-0.76-77.63%Miss-5.5%
    Jun 23
    		$-1.34$-1.24-8.06%Miss-482.6%
    Mar 23
    		$-1.38$-1.18-16.95%Miss-35.3%
    Dec 22
    		$-1.45$-1.21-19.83%Miss-302.8%
    Sep 22
    		$-1.28$-1.17-9.40%Miss-34.7%
    Jun 22
    		$-0.23N/A+77.23%Beat+73.3%
    Mar 22
    		$-1.02$-0.94-8.51%Miss-54.5%
    Dec 21
    		$-0.36N/A+57.14%Beat+41.9%
    Sep 21
    		$-0.95$-0.77-23.38%Miss-1800.0%
    Jun 21
    		$-0.86$-0.66-30.30%Miss-26.5%
    Mar 21
    		$-0.66$-0.60-10.00%Miss+0.0%
    Dec 20
    		$-0.62$-0.30-106.67%Miss-19.2%
    Sep 20
    		$-0.05N/A+85.29%Beat+90.0%
    Jun 20
    		$-0.68$-0.57-19.30%Miss-21.4%
    Mar 20
    		$-0.66$-0.50-32.00%Miss-22.2%
    Dec 19
    		$-0.52$-0.44-18.18%Miss-8.3%
    Sep 19
    		$-0.50$-0.49-2.04%Miss-25.0%
    Jun 19
    		$-0.56$-0.50-12.00%Miss-9.8%
    Mar 19
    		$-0.54$-0.47-14.89%Miss+3.6%
    Dec 18
    		$-0.48$-0.52+7.69%Beat+36.0%
    Sep 18
    		$-0.40$-0.52+23.08%Beat+33.3%
    Jun 18
    		$-0.51$-0.51+0.00%Beat+15.0%
    Mar 18
    		$-0.56$-0.58+3.45%Beat+9.7%
    Dec 17
    		$-0.75$-0.70-7.14%Miss-568.8%
    Sep 17
    		$-0.60$-0.62+3.23%Beat-181.1%
    Jun 17
    		$-0.60$-0.60+0.00%Beat-
    Mar 17
    		$-0.62$-0.61-1.64%Miss-
    Dec 16
    		$0.16$-0.26+161.54%Beat-
    Sep 16
    		$0.74$-0.28+364.29%Beat-

    Key Metrics

    Valuation
    P/E Ratio-11.42EV/EBITDA-15.82x
    Price/FCF-16.13xFCF Yield-6.20%
    Profitability
    Profit Margin0.00%Operating Margin-626.00%
    ROE-572.00%ROIC-56.36%
    Financial Health
    Debt/Equity-6.61xInterest Coverage-2.82x
    Current Ratio6.66xQuick Ratio6.66x
    Trading Statistics
    Beta0.38Avg Volume1.98M
    52-Week High$88.3152-Week Low$44.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$76.25
    SMA 20$76.56
    SMA 50$79.81
    SMA 200$69.64
    EMA 10$75.45
    EMA 20$76.53
    EMA 50$77.22
    EMA 200$69.38

    MACD

    Line: -1.22Signal: -0.87Hist: -0.35

    ADX

    ADX: 12.5+DI: 16.3-DI: 35.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$79.71

    Bollinger Bands

    Upper Band$81.46
    Lower Band$71.65
    %B Position1281%(Upper)
    Band Width-0.08

    RSI (14-Day)

    Neutral
    34.3

    Momentum Oscillators

    Stoch %K31.6
    Stoch %D50.6
    Williams %R-84.9
    ROC (10d)-6.5%
    Momentum-4.96
    CCI (20d)-225.7
    MFI (14d)34.6

    Volatility Measures

    ATR (14d)$2.74(3.9%)
    StdDev (20d)2.45
    Hist Vol42.9%(High)

    Volume Flow

    VWAP$70.67
    OBV33.0M
    AD Line9.6M
    CMF (20d)-0.047

    Volume Metrics

    Avg Vol (20d)2.0M
    Vol Ratio1.5x(High)
    VWMA (20d)$76.13

    Pivot Points

    R3$76.55
    R2$75.48
    R1$73.79
    Pivot Point$72.72
    S1$71.03
    S2$69.96
    S3$68.27

    Advanced Oscillators

    TSI-12.94
    Ultimate Osc39.2
    KST-57.71

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$28.62M$19.36M$17.75M$1.94M$66.77M$1.58M$17.18M$463,000$0$835,000$1.67M$378,000
    Cost of Revenue$5.59M$2.55M$2.86M$0$2.42M$1.58M$93.63M$0$0$0$84.98M$0
    Gross Profit$23.03M$16.80M$17.75M$1.94M$64.35M$0$17.18M$463,000$0$835,000$1.67M$378,000
    Operating Expenses$202.20M$200.42M$196.12M$168.69M$175.86M$155.63M$155.97M$141.26M$130.42M$127.07M$129.09M$122.64M
    R&D$97.81M$95.53M$104.40M$99.23M$110.14M$98.26M$93.63M$84.61M$79.60M$81.57M$84.98M$82.53M
    SG&A$104.40M$104.90M$91.72M$69.46M$65.72M$57.37M$62.34M$56.65M$50.82M$45.50M$44.11M$40.11M
    Operating Income$-179,172,000$-183,618,000$-178,366,000$-166,755,000$-111,506,000$-155,631,000$-139,040,000$-140,801,000$-130,172,000$-126,235,000$-127,418,000$-122,265,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$34.83M$33.34M$30.34M$147.57M$24.27M$22.95M$22.59M$22.30M$24.30M$17.32M$17.06M$14.00M
    Income Before Tax$-212,703,000$-217,053,000$-194,501,000$-316,426,000$-147,371,000$-175,077,000$-165,034,000$-177,599,000$-154,871,000$-143,556,000$-158,100,000$-129,422,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-198,762,000$-206,031,000$-183,031,000$-306,178,000$-134,370,000$-161,376,000$-150,020,000$-160,545,000$-143,318,000$-135,643,000$-136,896,000$-129,422,000
    EBITDA$-178,593,000$-182,214,000$-164,380,000$-168,872,000$-124,853,000$-156,005,000$-147,758,000$-163,981,000$-136,665,000$-129,128,000$-139,802,000$-117,308,000
    EBIT$-177,872,000$-183,718,000$-164,166,000$-168,855,000$-123,106,000$-152,131,000$-142,440,000$-155,301,000$-130,572,000$-126,235,000$-141,036,000$-115,426,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CYTK

    News

    Cytokinetics (CYTK) Could Be 29% Undervalued Following Favorable Phase 3 Aficamten Data

    Cytokinetics (CYTK) is considered potentially 29% undervalued, with a fair value estimated at $107.80 against its current share price of $76.84, following positive Phase 3 aficamten trial data. The company's ongoing investments in late-stage pipeline assets and its muscle biology platform are expected to drive future growth and reduce reliance on a single product. Investors are encouraged to review the full narrative, including risks like potential regulatory setbacks or high commercialization costs, and to consider other investment opportunities.

    Simply Wall Street•8/23/26•
    Bullish

    Cytokinetics (CYTK) Could Be 29% Undervalued Following Favorable Phase 3 Aficamten Data

    Cytokinetics (CYTK) is considered potentially 29% undervalued, with a fair value pegged at $107.80 compared to its last close of $76.84, following favorable topline results from its ACACIA-HCM Phase 3 aficamten trial. The company's ongoing investments in late-stage pipeline assets and its muscle biology platform are expected to drive future growth and improve long-term net margins, although risks from regulatory setbacks or high commercialization costs remain.

    Simply Wall Street•8/23/26•
    Bullish

    Cytokinetics CEO Sells 7,500 Shares Amid Strong Stock Performance

    Cytokinetics CEO Robert I. Blum sold 7,500 shares for $575,700 on August 10, 2026, after exercising options at a much lower strike price, reflecting gains from the company's strong stock performance. Despite the sale, Blum maintains a significant equity position, demonstrating continued alignment with shareholder interests. Analysts are highly optimistic about Cytokinetics, with 91% rating the stock as a buy and projecting a nearly 40% price increase.

    Intellectia AI•8/23/26•
    Bullish

    Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

    Cytokinetics CEO Robert I. Blum sold 7,500 shares of the company's stock for $575,700 after exercising stock options. Despite this sale, Blum retains a significant stake in Cytokinetics, indicating continued alignment with shareholder interests. Analysts maintain a favorable view of Cytokinetics stock, with a median one-year price target suggesting a nearly 40% gain.

    Yahoo Finance•8/22/26•
    Somewhat-Bullish

    Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

    Cytokinetics will present new data on aficamten for hypertrophic cardiomyopathy (HCM) at the European Society of Cardiology (ESC) Congress 2026, including Hot Line and Late-Breaking Science presentations for ACACIA-HCM. The company will also host an investor event to discuss the results. These presentations focus on both obstructive and non-obstructive forms of HCM, highlighting aficamten's potential in treating cardiac muscle dysfunction.

    GlobeNewswire•8/20/26•
    Somewhat-Bullish

    Frequently Asked Questions About CYTK

    Does CYTK pay dividends?
    Cytokinetics Inc (CYTK) does not currently pay a regular dividend.
    What is CYTK's market cap?
    Cytokinetics Inc (CYTK) has a market capitalization of $10.02B with a current stock price of $70.91.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In